Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Pediatric Hematology/Oncology
•
Leukemia
•
ALL
•
Hematology
How would you manage an early isolated CNS relapse in a pediatric patient with Ph positive ALL?
Related Questions
How do you incorporate blinatumomab into therapy for a pediatric or AYA patient with isolated CNS relapse of B-ALL, if at all?
In what situations do you use G-CSF for patients undergoing allogeneic HSCT to facilitate engraftment?
Would you offer intensive CNS prophylaxis to Ph negative B-ALL patients who have possible mandibular nerve involvement on MRI face?
For a pediatric patient with B-ALL who requires surgery during maintenance, what therapy modifications do you recommend to allow for optimal healing and minimal treatment disruption?
What is the preferred approach for an AYA patient with VHR B-ALL with iAMP21 mutation with an isolated early CNS relapse?
For AML patients, when do you stop antiinfective agents?
What are the treatment options for relapsed T-ALL in a patient who was nonadherent with AALL and hyper-CVAD regimens?
Are you including Bortezomib as standard of care in the upfront treatment of T lymphoblastic-lymphoma?
How long do you continue ATRA during induction in high risk acute promyelocytic leukemia?
Do you prefer to use 7+3 or CPX-351 as standard induction therapy in younger patients with AML-MRC or t-AML?
